DAVID DEAN, Healthcare and Biotechnology Analyst with Sprott Securities
Inc., has been in the investment business since 2000 and with Sprott
since 2002. He was previously with Yorkton Securities, Desjardins
Securities, and the Ottawa Heart Institute and the National Research
Council. He has an MSc (Physiology) from the University of Ottawa, 1995
and an MBA (Finance) from Queen’s University, 2000.
ROUNDTABLE FORUM: CANADIAN BIOTECHNOLOGY
January 10, 2005